KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biolife Solutions (BLFS) Asset Writedowns and Impairment (2016 - 2023)

Biolife Solutions (BLFS) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with -$69.9 million as the latest value for Q4 2022.

Quarterly Asset Writedowns and Impairment changed N/A to -$69.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$69.9 million through Dec 2024, changed N/A year-over-year, with the annual reading at $9.7 million for FY2023, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2022 was -$69.9 million at Biolife Solutions, down from $69.9 million in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $69.9 million in Q2 2022, with the low at -$69.9 million in Q4 2022.